Lishan MD - PAVmed Chairman CEO
| PAVM Stock | USD 0.97 0.03 3.19% |
Insider
Lishan MD is Chairman CEO of PAVmed Inc
| Age | 58 |
| Address | 360 Madison Avenue, New York, NY, United States, 10017 |
| Phone | 917-813-1828 |
| Web | https://www.pavmed.com |
PAVmed Management Efficiency
The company has return on total asset (ROA) of (0.8007) % which means that it has lost $0.8007 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (13.5806) %, meaning that it created substantial loss on money invested by shareholders. PAVmed's management efficiency ratios could be used to measure how well PAVmed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to drop to -2.13. In addition to that, Return On Capital Employed is likely to drop to 3.10. At this time, PAVmed's Non Current Assets Total are very stable compared to the past year. As of the 1st of December 2024, Asset Turnover is likely to grow to 0.08, while Total Assets are likely to drop about 23.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sean Menarguez | MaxCyte | N/A | |
| Roberto JD | Tela Bio | 56 | |
| Mitchell Hill | Inari Medical | 65 | |
| Andrew Hykes | Inari Medical | 51 | |
| MS MBA | Delcath Systems | 61 | |
| Jonathan Rothberg | Hyperfine | 60 | |
| Alok Gupta | Hyperfine | 58 | |
| Skott Greenhalgh | Tela Bio | 56 | |
| Waleed MD | TransMedics Group | 56 | |
| Thomas MD | Inari Medical | 51 | |
| Martha Morrell | Neuropace | 67 | |
| William Hoffman | Inari Medical | 57 | |
| Khan MD | Hyperfine | 50 | |
| Andre Marquette | Neuropace | N/A | |
| Paul Talmo | Tela Bio | 52 | |
| Anthony Dias | Delcath Systems | 57 | |
| John MS | Delcath Systems | 63 | |
| Kevin Muir | Delcath Systems | N/A | |
| Neela Paykel | Hyperfine | 53 | |
| Danilo DAlessandro | Clearpoint Neuro | 39 | |
| Antony Koblish | Tela Bio | 58 | |
Management Performance
| Return On Equity | -13.58 | ||||
| Return On Asset | -0.8 |
PAVmed Inc Leadership Team
Elected by the shareholders, the PAVmed's board of directors comprises two types of representatives: PAVmed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PAVmed. The board's role is to monitor PAVmed's management team and ensure that shareholders' interests are well served. PAVmed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PAVmed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Gordon, General VP | ||
| Lishan MD, Chairman CEO | ||
| Michael Parks, Vice Relations | ||
| Adrian Miller, VP Relations | ||
| Deepika Lakhani, Chief VP | ||
| Shaun MBA, Executive COO | ||
| Brian MD, Chief Affairs | ||
| Victoria Lee, Senior Officer | ||
| Victoria MD, Senior Officer | ||
| Dennis CPA, CFO President |
PAVmed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PAVmed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -13.58 | ||||
| Return On Asset | -0.8 | ||||
| Operating Margin | (13.98) % | ||||
| Current Valuation | 47.82 M | ||||
| Shares Outstanding | 10.74 M | ||||
| Shares Owned By Insiders | 10.38 % | ||||
| Shares Owned By Institutions | 14.59 % | ||||
| Number Of Shares Shorted | 269.9 K | ||||
| Price To Earning | (6.39) X | ||||
| Price To Book | 7.42 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PAVmed. If investors know PAVmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PAVmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.14) | Revenue Per Share 0.459 | Quarterly Revenue Growth 4.898 | Return On Assets (0.80) | Return On Equity (13.58) |
The market value of PAVmed Inc is measured differently than its book value, which is the value of PAVmed that is recorded on the company's balance sheet. Investors also form their own opinion of PAVmed's value that differs from its market value or its book value, called intrinsic value, which is PAVmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PAVmed's market value can be influenced by many factors that don't directly affect PAVmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PAVmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if PAVmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PAVmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.